Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02344355
Recruitment Status : Active, not recruiting
First Posted : January 22, 2015
Last Update Posted : February 1, 2022
Holden Comprehensive Cancer Center
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Bryan Allen, University of Iowa

Brief Summary:
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Drug: Temozolomide Radiation: radiation therapy Drug: Ascorbic Acid Phase 2

Detailed Description:

Standard treatment for glioblastoma multiforme (GBM) involves maximum safe surgical resection followed by radiation combined with temozolomide (a chemotherapy pill you take by mouth). After radiation, patients receive additional cycles of temozolomide (adjuvant chemotherapy).

Participants will:

  • receive high doses of intravenous (IV) ascorbate three times a week during the combined radiation and chemotherapy phase
  • receive high doses of intravenous (IV) ascorbate twice a week during adjuvant chemotherapy (after radiation)
  • complete health-related quality of life questionnaires pre-radiation, 4 weeks into radiation, 4 weeks after radiation, and then every 3 months. In addition, patients will complete neurocognitive testing pre-radiation, 4 weeks into radiation, 4 weeks after radiation, and approximately 9 months after initiating radiation therapy.

The adjuvant chemotherapy portion of this study lasts for 6 months. After that is completed, participants will go back to standard therapy for their cancer. Participants will continue to have life-long follow-up for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacological Ascorbate Combined With Radiation and Temozolomide in Glioblastoma Multiforme: A Phase 2 Trial
Actual Study Start Date : March 13, 2017
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : December 2024

Arm Intervention/treatment
Experimental: ascorbate, radiation, temozolomide

Concomitant therapy:

Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions

Adjuvant therapy:

Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions

Drug: Temozolomide

oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.

Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.

For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.

If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.

Other Names:
  • Temodar
  • Temodal

Radiation: radiation therapy
Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
Other Names:
  • EBRT
  • XRT
  • external beam radiation therapy

Drug: Ascorbic Acid

Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.

After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.

Other Names:
  • Vitamin C
  • Ascorbate
  • Pharmacological Ascorbate
  • 67457-118-50

Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: monthly up to 5 years post treatment ]
    From radiation day 1 until date of death from any cause.

Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: monthly up to 5 years post treatment ]
    From radiation day 1 to documented disease progression in MRI imaging as described by the RANO criteria

  2. Adverse Event Frequency [ Time Frame: monthly through 7 months post-radiation ]
    Categorize and quantify using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4 from radiation day 1 through 7 months post-radiation.

Other Outcome Measures:
  1. Health-related Quality of Life (HRQOL) [ Time Frame: monthly for 3 months, then every 3 months up to 5 years post treatment ]
    Measure health-related outcomes using the validated EORTC (European Organization for Research and Treatment of Cancer) questionnaires QLQ-C30 and BN-20.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to understand and willingness to sign informed consent (power of attorney and/or legally authorized representatives cannot sign on behalf of the patient)
  • Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme.
  • Diagnosis must be made by surgical biopsy or excision.
  • Therapy must begin ≤ 5 weeks after surgery or biopsy
  • Age ≥ 18 years
  • ECOG performance status 0-2. (KPS > 50)
  • Absolute neutrophil count (ANC) ≥ 1500 cells per mm3
  • Platelets ≥ 100,000 per mm3
  • Hemoglobin ≥ 8 g/dL
  • Creatinine ≤ 2.0 mg
  • Total bilirubin ≤ 1.5 mg/dL
  • ALT ≤ 3 times the institutional upper limit of normal
  • AST ≤ 3 times the institutional upper limit of normal
  • Tolerate one test dose (15g) of ascorbate.
  • Not pregnant.

Exclusion Criteria:

  • Recurrent high grade glioma
  • G6PD (glucose-6-phosphate dehydrogenase) deficiency.
  • Patients actively receiving insulin or using a finger-stick glucometer daily for blood glucose measurements
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide.
  • Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis.
  • Patients who are on the following drugs and cannot have a drug substitution: warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide.
  • Known active concurrent malignancy, as determined by treating physicians.
  • Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma.
  • Prior radiation therapy to the head or neck resulting in overlap of RT fields.
  • Patients receiving any other investigational agents (imaging agents are acceptable)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection that would result in a hospital stay or delay of treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or impact patient safety.
  • Pregnant women.
  • Breastfeeding women.
  • Known HIV-positive individuals. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02344355

Layout table for location information
United States, Iowa
Holden Comprehensive Cancer Center
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
Bryan Allen
Holden Comprehensive Cancer Center
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Bryan G. Allen, MD, PhD Assistant Professor, Department of Radiation Oncology, The University of Iowa
Layout table for additonal information
Responsible Party: Bryan Allen, Assistant Professor, Radiation Oncology, University of Iowa Identifier: NCT02344355    
Other Study ID Numbers: 201504786
First Posted: January 22, 2015    Key Record Dates
Last Update Posted: February 1, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data will be released publicly as per participant consent and IRB approval. Individual researchers should contact the research team for data sharing.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Study protocol and informed consent will be shared after primary completion. Statistical analysis plan will be shared with results reporting.
Access Criteria: An IRB-stamped signed usage agreement will be required in addition to a data sharing agreement between the academic centers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bryan Allen, University of Iowa:
Ascorbic Acid
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Ascorbic Acid
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protective Agents